logo
Ashley Fraser Bought 140% More Shares In Brightstar Resources

Ashley Fraser Bought 140% More Shares In Brightstar Resources

Yahoo24-04-2025

Those following along with Brightstar Resources Limited (ASX:BTR) will no doubt be intrigued by the recent purchase of shares by Ashley Fraser, Non-Executive Director of the company, who spent a stonking AU$4.2m on stock at an average price of AU$0.53. That increased their holding by a full 140%, which arguably implies the sort of confidence required for a shy sweet-natured nerd to ask the most popular kid in the school to go out on a date.
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.
Over the last year, we can see that the biggest insider purchase was by insider Jack Yetiv for AU$4.4m worth of shares, at about AU$0.015 per share. We do like to see buying, but this purchase was made at well below the current price of AU$0.51. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
While Brightstar Resources insiders bought shares during the last year, they didn't sell. The average buy price was around AU$0.024. To my mind it is good that insiders have invested their own money in the company. But we must note that the investments were made at well below today's share price. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
View our latest analysis for Brightstar Resources
Brightstar Resources is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.
For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It appears that Brightstar Resources insiders own 12% of the company, worth about AU$27m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
It is good to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Insiders likely see value in Brightstar Resources shares, given these transactions (along with notable insider ownership of the company). So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. At Simply Wall St, we've found that Brightstar Resources has 3 warning signs (2 can't be ignored!) that deserve your attention before going any further with your analysis.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Abbott Laboratories (NYSE:ABT) Partners With Tandem To Develop Dual Sensor Diabetes Solutions
Abbott Laboratories (NYSE:ABT) Partners With Tandem To Develop Dual Sensor Diabetes Solutions

Yahoo

timean hour ago

  • Yahoo

Abbott Laboratories (NYSE:ABT) Partners With Tandem To Develop Dual Sensor Diabetes Solutions

Tandem Diabetes Care, Inc. recently announced a significant collaboration with Abbott Laboratories to integrate Abbott's upcoming dual glucose-ketone sensor with Tandem's insulin delivery systems. This and other collaborations, such as the agreement with Sequel Med Tech, align with Abbott's strategic focus on enhancing diabetes care. Abbott's shares rose 3% over the last quarter, aligning closely with broader market trends, which advanced 13% over the past year. The company's robust product approvals and partnerships, alongside positive market sentiment, likely reinforced investor confidence in Abbott's growth trajectory amid generally favorable market conditions. You should learn about the 1 possible red flag we've spotted with Abbott Laboratories. Find companies with promising cash flow potential yet trading below their fair value. The recent collaboration between Tandem Diabetes Care, Inc. and Abbott Laboratories to integrate Abbott's dual glucose-ketone sensor has the potential to enhance Abbott's market positioning in diabetes care. This partnership, along with other strategic agreements, could support revenue growth in Abbott's Diabetes Care segment, though challenges such as tariffs and VBP program impacts in China remain. Abbott's five-year total return, including share price and dividends, stands at 63.31%, showcasing strong longer-term performance, despite some earnings forecast pressure. In the past year, Abbott's shares have risen above the US Medical Equipment industry, which saw a return of 8.2%. This outperformance over a shorter time horizon indicates that investor confidence remains buoyant. However, the expectation of declining earnings over the next three years, with a 10.1% decrease per year, highlights forecast challenges. This contrasts with a forecasted revenue growth of 6.9% annually, which is slower than the broader US market growth rate of 8.6% per year. The current share price of US$133.06 reflects a modest 5.2% discount to the consensus analyst price target of US$140.41, suggesting a perception of fair valuation compared to expected earnings growth and projected revenue increases. Insights from our recent valuation report point to the potential undervaluation of Abbott Laboratories shares in the market. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:ABT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Vertiv Holdings Co (NYSE:VRT) Unveils AI-Ready Cooling Architecture For NVIDIA GB300 NVL72 Platform
Vertiv Holdings Co (NYSE:VRT) Unveils AI-Ready Cooling Architecture For NVIDIA GB300 NVL72 Platform

Yahoo

timean hour ago

  • Yahoo

Vertiv Holdings Co (NYSE:VRT) Unveils AI-Ready Cooling Architecture For NVIDIA GB300 NVL72 Platform

Vertiv Holdings Co recently introduced an energy-efficient 142kW cooling and power reference architecture for the NVIDIA GB300 NVL72 platform, which aligns with broader trends driving technology innovation in data centers. Over the past quarter, Vertiv's stock price rose by 27%, a significant move partially supported by this product release. This rise contrasted with a more modest market uptick where indices like the S&P 500 and Nasdaq saw less dramatic increases, buoyed by benign inflation data and easing U.S.-China trade tensions. Vertiv's innovative strategies clearly supported its positive stock performance during this period. We've identified 2 possible red flags with Vertiv Holdings Co and understanding the impact should be part of your investment process. The latest GPUs need a type of rare earth metal called Neodymium and there are only 24 companies in the world exploring or producing it. Find the list for free. Vertiv Holdings Co's recent introduction of energy-efficient cooling and power solutions aligns well with its strategic focus on AI and data centers, potentially boosting future revenue and earnings. Over a remarkable three-year period, Vertiv's total shareholder return was very large at 1062.27%, reflecting favorable investor sentiment and strong business execution. Despite posting a compelling annual return, Vertiv shares underperformed the US Electrical industry, which saw a 24% increase over the past year. However, Vertiv has outpaced the broader US market, which returned 12.8% over the same period, underlining its robust performance. The collaboration with NVIDIA is likely to reinforce Vertiv's growth trajectory by catalyzing revenue growth through AI infrastructure projects. Analysts forecast a significant upward trend, with revenues expected to rise to approximately $12.2 billion by 2028. While the company's current share price is US$93.48, it remains below the consensus price target of US$108.14, indicating potential room for upside as the market adjusts to revised forecasts. Gain insights into Vertiv Holdings Co's future direction by reviewing our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:VRT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio

ASX Value Stock Picks Including Lynas Rare Earths For Estimated Growth
ASX Value Stock Picks Including Lynas Rare Earths For Estimated Growth

Yahoo

timean hour ago

  • Yahoo

ASX Value Stock Picks Including Lynas Rare Earths For Estimated Growth

As the ASX200 flirts with record highs, investor sentiment in Australia is cautiously optimistic, buoyed by potential trade deals and corporate activities like mergers and acquisitions. In such a climate, identifying undervalued stocks becomes crucial for investors looking to capitalize on market opportunities; companies with strong fundamentals and growth potential can offer promising prospects even amidst fluctuating sector performances. Name Current Price Fair Value (Est) Discount (Est) Superloop (ASX:SLC) A$2.85 A$4.92 42.1% Ridley (ASX:RIC) A$2.86 A$5.64 49.3% Praemium (ASX:PPS) A$0.685 A$1.16 40.8% Polymetals Resources (ASX:POL) A$0.825 A$1.54 46.3% PointsBet Holdings (ASX:PBH) A$1.195 A$2.05 41.8% Nuix (ASX:NXL) A$2.35 A$4.04 41.8% Nanosonics (ASX:NAN) A$4.35 A$6.92 37.1% Fenix Resources (ASX:FEX) A$0.285 A$0.47 38.9% Charter Hall Group (ASX:CHC) A$19.35 A$33.88 42.9% Capricorn Metals (ASX:CMM) A$9.12 A$14.62 37.6% Click here to see the full list of 32 stocks from our Undervalued ASX Stocks Based On Cash Flows screener. Underneath we present a selection of stocks filtered out by our screen. Overview: Lynas Rare Earths Limited operates in the exploration, development, mining, extraction, and processing of rare earth minerals in Australia and Malaysia with a market capitalization of A$8.04 billion. Operations: The company generates revenue primarily from its rare earth operations, amounting to A$482.82 million. Estimated Discount To Fair Value: 36.5% Lynas Rare Earths is trading at A$8.6, significantly below its estimated fair value of A$13.55, suggesting it may be undervalued based on discounted cash flow analysis. Despite a decline in profit margins from 33.2% to 10.5%, the company is expected to experience substantial earnings growth of over 61% annually, with revenue projected to grow at 38% per year, outpacing the broader Australian market's growth expectations. Our growth report here indicates Lynas Rare Earths may be poised for an improving outlook. Unlock comprehensive insights into our analysis of Lynas Rare Earths stock in this financial health report. Overview: Nanosonics Limited is a global infection prevention company with a market cap of A$1.32 billion. Operations: The company's revenue is primarily derived from its Healthcare Equipment segment, totaling A$183.97 million. Estimated Discount To Fair Value: 37.1% Nanosonics, trading at A$4.35, is valued below its estimated fair value of A$6.92, highlighting potential undervaluation based on discounted cash flow analysis. Earnings have grown 14.3% annually over the past five years and are forecast to increase significantly by 24.3% per year, outpacing the Australian market's growth rate of 11.6%. However, its future return on equity is projected to be relatively low at 13.9% in three years' time. The growth report we've compiled suggests that Nanosonics' future prospects could be on the up. Get an in-depth perspective on Nanosonics' balance sheet by reading our health report here. Overview: Ridley Corporation Limited, with a market cap of A$1.05 billion, provides animal nutrition solutions in Australia through its subsidiaries. Operations: The company's revenue is derived from two main segments: Bulk Stockfeeds, contributing A$894.26 million, and Packaged/Ingredients, accounting for A$389.70 million. Estimated Discount To Fair Value: 49.3% Ridley, trading at A$2.86, is priced below its estimated fair value of A$5.64, indicating potential undervaluation based on discounted cash flow analysis. Recent equity and fixed-income offerings might impact shareholder value in the short term. While revenue is expected to grow robustly at 20.7% annually, earnings growth of 16.6% per year surpasses the Australian market average but remains moderate compared to significant benchmarks. The company's dividend history is unstable, and return on equity forecasts are modest at 14.4%. Our expertly prepared growth report on Ridley implies its future financial outlook may be stronger than recent results. Click to explore a detailed breakdown of our findings in Ridley's balance sheet health report. Navigate through the entire inventory of 32 Undervalued ASX Stocks Based On Cash Flows here. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:LYC ASX:NAN and ASX:RIC. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store